Searched for
NOVARTIS CEO
Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...- DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive CapitalAI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of t...
- Anthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its boardAnthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI syst...
- Market volatility derails Novartis' plan to sell stake in its India armNovartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strate...
- Novartis CEO 'very confident' on sales target, doesn't fear patent cliffNovartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday.
- India needs regulatory data protection to attract drug research: Novartis CEOIf one looks at any place in the world where there is significant fundamental drug research happening from multinational firms, there is re...
- When you are from different background and in different country, you are scrutinised more, says Novartis CEOAsserting that it's a really exciting moment to be in the world of medicine and R&D, Narasimhan said: "RNA therapeutics are opening up a wh...
- COVID-19: Novartis to begin HCQ trialsEven as there is still question hanging over the efficacy of hydroxychloroquine (HCQ) as medication for Covid-19, Swiss drug maker Novartis...
- Novartis, U.S. regulators agree to malaria drug hydroxychloroquine trial against COVID-19Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-...
- Don’t foresee any disruptions due to Covid-19: Vasant Narasimhan, CEO, NovartisNovartis is one of the oldest pharma MNCs known for anti-cancer and anti-diabetic drugs. Despite the patent expiry for its popular anti-dia...
- Three Indian-origin CEOs dine with Donald Trump in DavosVas Narasimhan from Novartis; Rajeev Suri from Nokia & Punit Renjen from Deloitte were part of the dinner that took place on the sidelines ...
- Who is Vas Narasimhan? All about the new global chief executive of Swiss pharma giant NovartisHere’s everything that you need to know about the doctor-turned-CEO.
- Novartis CEO Jimenez to quit giving reins to Vasant NarasimhanJimenez is handing over the reins at a crucial juncture, with the drugmaker yet to make a decision on the future of its ailing Alcon eye-ca...
- Novartis India surges 20% as parent company strikes $15 billion deal with GSK, LillyNovartis on Tuesday said it will buy GSK's oncology products business. Separately, Novartis said it will sell off its animal health divisio...
- Novartis bids $ 470 mn for US cancer diagnostic firmIt says the price represents a 39 per cent premium over Genoptix's share value on Dec. 13, 2010, when rumors of a sale sparked a price surg...
- Novartis concludes acquisition of 77% Alcon stake from NestleNovartis on Thursday said it has concluded a $28.3 billion deal with Alcon Inc that will give the Swiss drug-maker a controlling stake in t...
- Novartis posts 7% rise in Q1 net profitPharmaceuticals maker Novartis AG reported a 7 percent rise in first-quarter net income on Monday on the back of a declining dollar and sol...
- Norway asks Novartis to withdraw caseSwedish government backs India in patent fight against pharma-major Novartis.
- Nestle buys baby food biz off NovartisSwiss food giant Nestle is buying the Gerber baby food business off pharma major Novartis for $5.5 bn.
- Novartis seeks EU MPs' support on patents caseThe final hearings on the Novartis petition challenging the clause of the Indian Patent Act Amendment (2005), which does not accord patents...
Load More
